51 related articles for article (PubMed ID: 23610449)
1. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
End D; Molina A; Todd M; Meyers ML
Cancer Res; 2013 May; 73(9):2926. PubMed ID: 23610449
[No Abstract] [Full Text] [Related]
2. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
Richards J; Lim AC; Hay CW; Taylor AE; Wingate A; Nowakowska K; Pezaro C; Carreira S; Goodall J; Arlt W; McEwan IJ; de Bono JS; Attard G
Cancer Res; 2012 May; 72(9):2176-82. PubMed ID: 22411952
[TBL] [Abstract][Full Text] [Related]
3. Re: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Anand AU; Bjartell A
Eur Urol; 2015 Feb; 67(2):349-50. PubMed ID: 25760252
[No Abstract] [Full Text] [Related]
4. Re: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Taneja SS
J Urol; 2015 Feb; 193(2):538. PubMed ID: 25617272
[No Abstract] [Full Text] [Related]
5. Re: AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer.
Sun M; Abdollah F
Eur Urol; 2015 Jul; 68(1):162-3. PubMed ID: 26088731
[No Abstract] [Full Text] [Related]
6. Resistance to androgen-pathway drugs in prostate cancer.
Steinestel J; Schrader AJ; Luedeke M
N Engl J Med; 2014 Dec; 371(23):2234. PubMed ID: 25470703
[No Abstract] [Full Text] [Related]
7. Resistance to androgen-pathway drugs in prostate cancer.
Ozaki Y; Miura Y; Takano T
N Engl J Med; 2014 Dec; 371(23):2233-4. PubMed ID: 25470702
[No Abstract] [Full Text] [Related]
8. Resistance to androgen-pathway drugs in prostate cancer.
Şendur MA; Akıncı MB; Yalçın B
N Engl J Med; 2014 Dec; 371(23):2233. PubMed ID: 25470701
[No Abstract] [Full Text] [Related]
9. Resistance to androgen-pathway drugs in prostate cancer.
Antonarakis ES; Nakazawa M; Luo J
N Engl J Med; 2014 Dec; 371(23):2234. PubMed ID: 25470700
[No Abstract] [Full Text] [Related]
10. Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer.
Sartor O; Dong Y
Asian J Androl; 2015; 17(3):439-40. PubMed ID: 25532583
[TBL] [Abstract][Full Text] [Related]
11. Targeting the androgen receptor in prostate cancer--a resilient foe.
Nelson PS
N Engl J Med; 2014 Sep; 371(11):1067-9. PubMed ID: 25184629
[No Abstract] [Full Text] [Related]
12. Prostate cancer: predicting resistance-AR-V7 is a potential biomarker.
Stone L
Nat Rev Urol; 2014 Nov; 11(11):606. PubMed ID: 25266571
[No Abstract] [Full Text] [Related]
13. Words of wisdom. Re: androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.
Schrader AJ; Schrader MG; Cronauer MV
Eur Urol; 2013 Jul; 64(1):169-70. PubMed ID: 23746320
[No Abstract] [Full Text] [Related]
14. Words of wisdom: re: androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.
Luo J; Pienta KJ
Eur Urol; 2013 Aug; 64(2):339-40. PubMed ID: 23830228
[No Abstract] [Full Text] [Related]
15. CANCER. Cancer therapies that are gone with the Wnt.
Nanus DM; Giannakakou P
Science; 2015 Sep; 349(6254):1283-4. PubMed ID: 26383936
[No Abstract] [Full Text] [Related]
16. Estrogen-Mediated Activation of H875Y Androgen Receptor Mutation in a Prostate Cancer Patient.
Vasudevamurthy AK; Ledet E; Garvey C; Lewis BE; Sartor O
Clin Genitourin Cancer; 2017 Feb; 15(1):e111-e113. PubMed ID: 27527401
[No Abstract] [Full Text] [Related]
17. Prostate cancer: Wnt signalling induces resistance.
Sidaway P
Nat Rev Urol; 2015 Nov; 12(11):597. PubMed ID: 26439505
[No Abstract] [Full Text] [Related]
18. Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.
Agarwal N; Hutson TE; Vogelzang NJ; Sonpavde G
Future Oncol; 2010 May; 6(5):665-79. PubMed ID: 20465382
[TBL] [Abstract][Full Text] [Related]
19. Role of androgens in abiraterone resistance.
Colloca G
J Clin Oncol; 2012 Oct; 30(28):3561-2: author reply 3562. PubMed ID: 22915660
[No Abstract] [Full Text] [Related]
20. Abiraterone. Cougar Biotechnology.
Madan RA; Arlen PM
IDrugs; 2006 Jan; 9(1):49-55. PubMed ID: 16374734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
